JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

13.51 2.5

Overview

Share price change

24h

Current

Min

12.92

Max

13.51

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.076 67.147
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+50.38% upside

Market Stats
By TradingEconomics
Market Cap	2.3B
Previous open	11.01
Previous close	13.51

News Sentiment

By Acuity

50%

50%

176 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 maj 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 maj 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 maj 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 maj 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 maj 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 maj 2026, 22:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 maj 2026, 22:26 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 maj 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 maj 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 maj 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 maj 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 maj 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 maj 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 maj 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 maj 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 maj 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

50.38% upside

12 Months Forecast

Average 20 USD 50.38%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

176 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Other stocks from the sector

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat